Published in Gastroenterology on October 01, 1996
Malignant Ascites Alfapump® Study (ProMAS) | NCT04076566
Prospective Evaluation of PleurX Drain for Treatment of Cirrhotic Refractory Ascites | NCT04569565
Guidelines on the management of ascites in cirrhosis. Gut (2006) 1.81
Recommendations for the use of albumin and immunoglobulins. Blood Transfus (2009) 1.75
The hepatorenal syndrome. Gut (2001) 1.10
Kidneys in chronic liver diseases. World J Gastroenterol (2012) 1.10
Are all colloids same? How to select the right colloid? Indian J Anaesth (2009) 1.06
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol (2006) 1.03
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Albumin for end-stage liver disease. Korean J Intern Med (2012) 0.93
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut (2001) 0.92
Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol (2011) 0.92
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Management of liver cirrhosis between primary care and specialists. World J Gastroenterol (2011) 0.89
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Human albumin in the management of complications of liver cirrhosis. Crit Care (2012) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol (2011) 0.86
Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol (2016) 0.85
Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol (2015) 0.84
Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol (2011) 0.83
Is there still a need for albumin infusions to treat patients with liver disease? Gut (2000) 0.83
Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int (2013) 0.82
Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol (2014) 0.82
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res (2010) 0.82
Paracentesis-induced circulatory dysfunction: a primer for the interventional radiologist. Semin Intervent Radiol (2014) 0.81
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol (2005) 0.80
Clinical use of albumin. Blood Transfus (2013) 0.79
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterol (2014) 0.79
The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction. Clin Mol Hepatol (2015) 0.78
Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. Yonsei Med J (2013) 0.77
Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised. Transfus Med Hemother (2016) 0.76
Ascites. Curr Treat Options Gastroenterol (2001) 0.76
Should albumin be used in all patients with spontaneous bacterial peritonitis? Can J Gastroenterol (2011) 0.76
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therap Adv Gastroenterol (2017) 0.75
5 Human Albumin. Transfus Med Hemother (2009) 0.75
Key Controversies in Colloid and Crystalloid Fluid Utilization. Hosp Pharm (2015) 0.75
Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed (2004) 0.75
Acute renal injury after partial hepatectomy. World J Hepatol (2016) 0.75
Acute Kidney Injury in Patients with Cirrhosis. J Clin Transl Hepatol (2015) 0.75
Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. Pak J Med Sci (2015) 0.75
Management of refractory ascites in cirrhosis: Are we out of date? World J Hepatol (2016) 0.75
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Randomized, controlled pilot study comparing large-volume paracentesis using wall suction and traditional glass vacuum bottle methods. Therap Adv Gastroenterol (2014) 0.75
What we know about paracentesis induced circulatory dysfunction? Clin Mol Hepatol (2015) 0.75
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol (2016) 0.75
Managing complications in cirrhotic patients. United European Gastroenterol J (2015) 0.75
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75
AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus (2016) 0.75
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol (2012) 0.75
NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatol (2013) 0.75
Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect (2017) 0.75
Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One (2017) 0.75
Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo) (2017) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology (1996) 4.54
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Hepatitis C virus antibodies among risk groups in Spain. Lancet (1989) 3.66
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol (2000) 3.43
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis (2009) 3.22
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Gender differences in children's hospitalization in Catalonia: another inequality? Acta Paediatr (1999) 2.96
Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis (2001) 2.76
Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology (2001) 2.74
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy (2011) 2.50
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Laparoscopic treatment vs open surgery in the solution of major incisional and abdominal wall hernias with mesh. Surg Endosc (1999) 2.46
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J (2000) 2.45
The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol (2001) 2.42
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology (1990) 2.31
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology (1995) 1.84
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology (1988) 1.73
Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology (1984) 1.73
Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology (1993) 1.69
Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol (2007) 1.68
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66